|
|||||
|
|
| 利奈唑胺和万古霉素治疗重症医学科院内耐甲氧西林金黄色葡萄球菌肺炎疗效及安全性研究 | |
| 引用本文： | 张胜靖,林梅瑟,张贻雯. 利奈唑胺和万古霉素治疗重症医学科院内耐甲氧西林金黄色葡萄球菌肺炎疗效及安全性研究[J]. 中国实用内科杂志, 2011, 0(9) |
| 作者姓名： | 张胜靖 林梅瑟 张贻雯 |
| 作者单位： | 温州市中医院ICU; |
| 摘 要： | 目的比较利奈唑胺与万古霉素对ICU患者耐甲氧西林金黄色葡萄球菌(MRSA)肺部感染的疗效及安全性。方法对2008年5月至2010年11月温州市中医院收治的72例肺部MRSA感染的患者,分别给予利奈唑胺(0.6 g/次,每日2次)和万古霉素(1.0 g/次,每日2次)治疗,观察并比较两种方法的临床疗效、细菌学疗效及不良反应。结果万古霉素与利奈唑胺治疗MRSA的治愈率分别为25.7%和18.9%,临床总有效率分别为65.7%和51.4%,细菌清除率分别为71.4%和48.6%,不良反应总发生率为8.5%和5.4%,两组间MRSA治愈率、总有效率和不良反应总发生率比较差异无统计学意义(P>0.05),细菌清除率比较差异有统计学意义(P<0.05)。结论对于ICU患者肺部MRSA感染,利奈唑胺与万古霉素敏感率均很高,总体疗效相似,且安全性及耐受性较好,利奈唑胺痰菌清除率略高于后者。 |
| 关 键 词： | 利奈唑胺 万古霉素 肺部感染 耐甲氧西林金葡 |
Efficacy and safety of Linezolid versus Vancomycin in treatment of hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus in ICU |
|
| ZHANG Sheng-jing,LIN Mei-se,ZHANG Yi-wen. Efficacy and safety of Linezolid versus Vancomycin in treatment of hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus in ICU[J]. Chinese Journal of Practical Internal Medicine, 2011, 0(9) | |
| Authors: | ZHANG Sheng-jing LIN Mei-se ZHANG Yi-wen |
| Affiliation: | ZHANG Sheng-jing,LIN Mei-se,ZHANG Yi-wen.Department of ICU,Wenzhou Traditional Chinese Medicine Hospital,Wenzhou 325000,China |
| Abstract: | Objective To compare the efficacy and safety of linezolid versus vancomycin in treatment of pneumonia caused by methicillin-resistant Staphylococcus aureus(MRSA) in ICU.Methods Between May 2008 and November 2010,72 patients with MRSA pneumonia were admitted to Wenzhou Traditional Chinese Medicine Hospital.The patients received 600 mg linezolid or 1 g vancomycin every 12 h daily.The therapeutic effect,bacterial clearance and adverse events were compared between the two treatments.Results The rates of full re... |
| Keywords: | linezolid vancomycin pneumonia MRSA |
| 本文献已被 CNKI 等数据库收录！ | |